Molecular Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Cancer Research 6, 585-591, April 1, 2008. doi: 10.1158/1541-7786.MCR-07-2158
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Karpinski, P.
Right arrow Articles by Blin, N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karpinski, P.
Right arrow Articles by Blin, N.


Cancer Genes and Genomics

The CpG Island Methylator Phenotype Correlates with Long-Range Epigenetic Silencing in Colorectal Cancer

Pawel Karpinski1, David Ramsey3, Zygmunt Grzebieniak2, Maria M. Sasiadek1 and Nikolaus Blin4

1 Department of Genetics and 2 Second Department of General and Oncological Surgery, Wroclaw Medical University, Wroclaw, Poland; 3 Department of Statistics and Mathematics, University of Limerick, Plassey, Limerick, Ireland; and 4 Division of Molecular Genetics, Institute of Human Genetics, University of Tuebingen, Tuebingen, Germany

Requests for reprints: Maria Malgorzata Sasiadek, Departament of Genetics, Wroclaw Medical University, ul. Marcinkowskiego 1, 50-368 Wroclaw, Poland. Phone: 48-71-7841256; Fax: 48-71-7840063. E-mail: sasiadek{at}gen.am.wroc.pl

The CpG island methylator phenotype (CIMP), characterized by an exceptionally high frequency of methylation of discrete CpG islands, is observed in 18% to 25% of sporadic colorectal cancers. Another hypermethylation pattern found in colorectal cancers, termed long-range epigenetic silencing, is associated with DNA/histone methylation in three distinct gene clusters at chromosome 2q14.2, showing that DNA hypermethylation can span larger chromosomal domains and lead to the silencing of flanking, unmethylated genes. We investigated whether these two phenotypes are interrelated in colorectal cancers. The CIMP status of 148 sporadic colorectal cancers was determined by methylation-specific PCR. We determined the BRAF V600E mutation by mutant allele–specific PCR amplification. The methylation status of the MLH1 gene and of three CpG islands (EN1, SCTR, and INHBB), corresponding to three distinct clusters along 2q14.2, was determined by methylation-specific PCR. The average number of sites showing methylation in CIMP+ tumors was 2.21, compared with 1.22 for CIMP– individuals, and this difference was highly significant (P = 3.6 x 10–8, Mann-Whitney test). Moreover, all CIMP+ tumors showed hypermethylation of at least one of these loci, in contrast to CIMP– tumors, where 18 (16%) samples remained unmethylated. The mean number of simultaneously hypermethylated CpG islands at 2q14.2 differs significantly between CIMP– and CIMP+ tumors, suggesting varying effects of domain silencing in this region. Given that the number of hypermethylated loci at 2q14.2 likely affects the range of silenced flanking genes, high frequency of simultaneous hypermethylation of three CpG islands (EN1, SCTR, and INHBB) may have potential influence on specific characteristics of CIMP+ colorectal cancers. (Mol Cancer Res 2008;6(4):585–91)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2008 by the American Association for Cancer Research.